Mobile

EVALUATION OF THE EFFICACY, SAFETY AND TOLERABILITY OF THE CONCURRENT ADMINISTRATION OF CHF 4226 HFA pMDI AND EXTRAFINE BUDESONIDE HFA pMDI, BOTH GIVEN ONCE OR TWICE DAILY (2μg + 200μg qd or 1μg + 100...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000038-11

EVALUATION OF THE EFFICACY, SAFETY AND TOLERABILITY OF THE CONCURRENT ADMINISTRATION OF CHF 4226 HFA pMDI AND EXTRAFINE BUDESONIDE HFA pMDI, BOTH GIVEN ONCE OR TWICE DAILY (2μg + 200μg qd or 1μg + 100μg bid) OVER AN 8-WEEK RANDOMIZED DOUBLE-BLIND TREATMENT PERIOD IN ADULT PATIENTS WITH MODERATE PERSISTENT ASTHMA AND PRESENTING WITH SYMPTOMS ON EXISTING INHALED CORTICOSTEROID THERAPY

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary: To demonstrate the non inferiority in terms of morning PEF of the "free combination" of CHF 4226 HFA pMDI + extrafine budesonide HFA pMDI given once daily in the evening (2µg + 200µg qd) versus CHF 4226 HFA pMDI + extrafine budesonide HFA pMDI given twice daily (1µg + 100µg bid).

Critère d'inclusion

  • Moderate persistent asthma sub optimally controlled on existing therapy

Liens